quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:06:08·56d
SECFiling
Intellia Therapeutics Inc. logo

SEC Form 10-K filed by Intellia Therapeutics Inc.

NTLA· Intellia Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • NTLA
    Intellia Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 2UpdateWilliam Blair-
  • Nov 12UpdateWolfe Research-
  • Nov 11UpdateEvercore ISI$8.00
  • Nov 7UpdateAnalyst$5.00
  • Oct 28UpdateRBC Capital Mkts$14.00
  • Oct 28UpdateBernstein-

Related

  • SEC13d
    SEC Form 8-K filed by Intellia Therapeutics Inc.
  • PR15d
    The Credibility Filter Wall Street Uses to Sort Biotech Winners
  • PR20d
    Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Intellia Therapeutics Inc.
  • PR48d
    Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER51d
    EVP, General Counsel Basta James was granted 46,080 shares and sold $16,688 worth of shares (1,211 units at $13.78), increasing direct ownership by 40% to 156,794 units (SEC Form 4)
  • INSIDER51d
    President and CEO Leonard John M was granted 156,400 shares, increasing direct ownership by 15% to 1,169,739 units (SEC Form 4)
  • INSIDER51d
    VP, Chief Accounting Officer Dube Michael P was granted 17,250 shares, increasing direct ownership by 33% to 69,527 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022